What is the recommended progesterone (Progesterone) dosing regimen for irregular bleeding?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Progesterone Dosing Regimens for Irregular Bleeding

For irregular uterine bleeding, the recommended first-line progesterone regimen is oral medroxyprogesterone acetate 10 mg daily for 10-14 days per cycle, or micronized progesterone 200 mg daily for 12-14 days every 28 days. 1, 2

First-Line Treatment Options

Oral Progesterone Options:

  • Medroxyprogesterone acetate (MPA): 10 mg daily for 10-14 days beginning on day 16 of each cycle 1, 3
  • Micronized progesterone (MP): 200 mg daily for 12-14 days every 28 days 2

Alternative Delivery Methods:

  • Vaginal progesterone: Micronized progesterone 200 mg daily for 12-14 days every 28 days 2
  • Levonorgestrel-releasing IUD: Most effective option with up to 97% reduction in bleeding by 6 months 1, 3

Treatment Selection Algorithm

  1. Determine if contraception is required:

    • If contraception needed: Consider levonorgestrel IUD (most effective) or combined hormonal contraceptives 1
    • If contraception not needed: Proceed with cyclic progesterone therapy 2
  2. Determine patient preference regarding withdrawal bleeding:

    • If withdrawal bleeding acceptable: Use cyclic progesterone regimen
    • If withdrawal bleeding not desired: Use continuous combined regimen 2
  3. Select appropriate regimen based on severity:

    • For mild-moderate bleeding: Oral/vaginal progesterone for 10-14 days per cycle
    • For severe bleeding: Consider levonorgestrel IUD or continuous combined therapy 1

Dosing Specifics by Scenario

For Cyclic Therapy (with withdrawal bleeding):

  • Transdermal 17β-estradiol (if estrogen needed) administered continuously
  • Add oral progesterone (MPA 10 mg daily or MP 200 mg daily) for 12-14 days every 28 days 2

For Continuous Therapy (avoiding withdrawal bleeding):

  • Combined tablets containing estradiol and progestin administered continuously
  • Example: 1-2 mg estradiol with 5 mg dydrogesterone or 2 mg dienogest 2

Efficacy Considerations

The levonorgestrel-releasing IUD is significantly more effective than oral medroxyprogesterone acetate for treating heavy menstrual bleeding:

  • LNG-IUD reduces menstrual blood loss by median of 128.8 mL
  • Oral MPA reduces menstrual blood loss by median of only 17.8 mL
  • Success rates: 84.8% for LNG-IUD vs 22.2% for oral MPA 3

Common Side Effects and Management

  • Breakthrough bleeding: Common with progestin-only methods, especially in first 3-6 months 4
  • Amenorrhea: Occurs in approximately 50% of LNG-IUD users by 2 years (expected effect) 1
  • Drowsiness: Can occur with oral micronized progesterone; administering at bedtime minimizes this effect 5
  • Iron deficiency: Consider iron supplementation if bleeding is heavy or prolonged 1

Important Caveats

  • Higher doses of medroxyprogesterone acetate (50 mg daily) may be needed for conditions like endometriosis but are not typically used for irregular bleeding alone 6
  • Women with excessive bleeding unresponsive to medical therapy should undergo endometrial biopsy to rule out underlying pathology 1
  • Consider structural causes of bleeding (polyps, fibroids) if response to hormonal therapy is inadequate 1
  • Micronized progesterone may have fewer metabolic and vascular side effects compared to synthetic progestins 5

References

Guideline

Management of Excessive Uterine Bleeding

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Unscheduled vaginal bleeding with progestin-only contraceptive use.

American journal of obstetrics and gynecology, 2017

Research

Oral micronized progesterone.

Clinical therapeutics, 1999

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.